tiprankstipranks
Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316
PremiumThe FlyAcrivon announces initial patient dosing in Phase 1 trial of ACR-2316
1M ago
Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital
Premium
The Fly
Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital
2M ago
Acrivon Therapeutics: Promising Trial Results and FDA Clearance
Premium
Company Announcements
Acrivon Therapeutics: Promising Trial Results and FDA Clearance
2M ago
Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer
PremiumThe FlyAcrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer
3M ago
Acrivon Therapeutics sees cash runway into 2H26
Premium
The Fly
Acrivon Therapeutics sees cash runway into 2H26
3M ago
Acrivon Therapeutics reports Q2 EPS (52c), consensus (60c)
Premium
The Fly
Acrivon Therapeutics reports Q2 EPS (52c), consensus (60c)
3M ago
Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
PremiumThe FlyAcrivon Therapeutics price target raised to $25 from $18 at BMO Capital
7M ago
Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
Premium
The Fly
Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
7M ago
Acrivon Therapeutics Inc trading resumes
Premium
The Fly
Acrivon Therapeutics Inc trading resumes
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100